Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock [Member] Series C Preferred Stock	Common Stock [Member] Series D Preferred Stock	Common Stock [Member]	Additional Paid-in Capital [Member] Series C Preferred Stock	Additional Paid-in Capital [Member] Series D Preferred Stock	Additional Paid-in Capital [Member]	Accumulated Deficit [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Deferred Compensation [Member]	Series B Preferred Stock	Series C Preferred Stock	Series D Preferred Stock	Cumulative Effect, Period of Adoption, Adjustment [Member]	Total
Beginning Balance at Oct. 31, 2018			$ 1			$ 1,073,463		$ (990,867)	$ (403)	$ (363)	$ 363					$ 82,194
Beginning Balance at (in shares) at Oct. 31, 2018			7,972,686
Sale of common stock, net of fees			$ 12			43,654										43,666
Sale of common stock, net of fees (in shares)			119,128,677
Common stock issued, non-employee compensation						102										$ 102
Common stock issued, non-employee compensation, (in shares)			29,454													29,454
Share based compensation						2,804										$ 2,804
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans						(200)										(200)
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans (shares)			52,607
Series A Warrant Exchange (shares)			500,000
Convertible preferred stock conversions		$ 6		$ 15,489	$ 31,177								$ 15,489	$ 31,183
Series C convertible preferred stock conversions (shares)	3,914,218												3,914,218
Series C convertible preferred stock adjustment for beneficial conversion feature						6,586										6,586
Series C convertible stock redemption value adjustments						(14,597)										(14,597)
Preferred dividends - Series B						(3,231)						$ (3,231)				(3,231)
Series D Preferred stock redemption accretion						(3,793)										(3,793)
Series D convertible preferred stock conversions (shares)		62,040,496
Effect of foreign currency translation									(244)							(244)
Adjustment for deferred compensation										(103)	103
Adjustment for deferred compensation (in shares)			(29,454)
Net loss								(77,568)								(77,568)
Ending Balance at Oct. 31, 2019			$ 19			1,151,454	$ (6,654)	(1,075,089)	(647)	(466)	466				$ (6,654)	75,737
Ending Balance at (in shares) at Oct. 31, 2019			193,608,684
Sale of common stock, net of fees			$ 9			171,902										171,911
Sale of common stock, net of fees (in shares)			86,307,932
Orion warrant exercises and other warrant exercises			$ 1			37,059										37,060
Orion warrant exercises and other warrant exercises (in shares)			14,696,320
Common stock issued, non-employee compensation						104										$ 104
Common stock issued, non-employee compensation, (in shares)			58,303													58,303
Share based compensation						1,868										$ 1,868
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans						(3)										(3)
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans (shares)			49,434
Reclassification of value of share based compensation upon approval of authorized shares for grant						401										401
Preferred dividends - Series B						(3,331)						(3,331)				(3,331)
Effect of foreign currency translation									(92)							(92)
Adjustment for deferred compensation										34	(34)
Adjustment for deferred compensation (in shares)			(13,915)
Net loss								(89,107)								(89,107)
Ending Balance at Oct. 31, 2020			$ 29			1,359,454		(1,164,196)	(739)	(432)	432					$ 194,548
Ending Balance at (in shares) at Oct. 31, 2020			294,706,758													294,706,758
Sale of common stock, net of fees			$ 8			525,887										$ 525,895
Sale of common stock, net of fees (in shares)			69,074,573
Orion warrant exercises and other warrant exercises						22,093										22,093
Orion warrant exercises and other warrant exercises (in shares)			2,714,026
Common stock issued, non-employee compensation						275										$ 275
Common stock issued, non-employee compensation, (in shares)			31,889													31,889
Share based compensation						4,293										$ 4,293
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards						(331)										(331)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (shares)			108,511
Preferred dividends - Series B						(3,200)						$ (3,200)				(3,200)
Effect of foreign currency translation									(80)							(80)
Adjustment for deferred compensation										(154)	154
Adjustment for deferred compensation (in shares)			(17,019)
Release of a share reserve			(45)
Net loss								(101,055)								(101,055)
Ending Balance at Oct. 31, 2021			$ 37			$ 1,908,471		$ (1,265,251)	$ (819)	$ (586)	$ 586					$ 642,438
Ending Balance at (in shares) at Oct. 31, 2021			366,618,693													366,618,693